X4 Pharmaceuticals (XFOR) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
10 Nov, 2026Strategic focus and financial discipline
Since the new management team arrived in August 2025, raised $240M and restructured leadership; operations are now almost entirely focused on the pivotal 4WARD trial.
Financial discipline is intended to preserve enough cash to support commercialization of mavorixafor in chronic neutropenia; cash was $188M and was expected to fund commercialization.
4WARD trial design and timing
Phase III, double-blind, placebo-controlled study in symptomatic primary chronic neutropenia; 126 patients randomized 1:1, with mavorixafor or placebo, each with or without G-CSF.
Co-primary endpoints over 12 months: reduction in annualized infection rate and ANC increase of at least 500 cells/µL on at least three occasions; trial powered for a one-third infection-rate reduction.
Enrollment remained on track for completion by year-end 2026; top-line 4WARD results expected by the end of Q1 2028, 8–10 weeks after the last patient enters.
Management characterized a one-third infection reduction as clinically meaningful, citing 6,300 primary chronic neutropenia patients hospitalized with infections in 2025 and an average four-day stay.
Treatment landscape and 4STEPS
Current care includes G-CSF, long-term antibiotics, or watchful waiting; G-CSF is approved for severe neutropenia, has variable use and dosing, and can involve injections, bone pain, and long-term malignancy concerns.
Mavorixafor could offer the first oral therapy for this disease; management sees potential use alongside G-CSF or antibiotics, with dose reductions or discontinuation possible.
4STEPS is a directional study in patients already taking G-CSF, designed to inform dose titration and day-to-day prescribing; first patient expected in Q1 2027, with data anticipated alongside 4WARD results.
4STEPS safety data will enter the FDA safety database; any role in label support would be considered after 4WARD results.
Latest events from X4 Pharmaceuticals
- 4WARD enrollment targets year-end 2026, with topline data expected in Q1 2028.XFOR
Stifel 2026 Healthcare Conference 2026 - Higher product sales and 4WARD progress accompany debt refinancing and runway into Q1 2029.XFOR
Q3 2026 - Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFOR
Corporate presentation - Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029.XFOR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue was $8.8M, net loss improved, and cash runway extends into 2029.XFOR
Q2 2026 - XOLREMDI launch gains traction as Phase 3 CN trial advances and global expansion plans progress.XFOR
Stifel 2024 Healthcare Conference - Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFOR
Q2 2024 - Mavorixafor durably increased ANC and showed good tolerability in chronic neutropenia Phase 2.XFOR
Study Update